Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566408 | 0.84 | AXL (0.49) | AXLSORT1GAAALDH1A1MAPT | |
| SCHEMBL6091136 | 0.82 | ESR1 (0.43) | AXLSORT1GAAALDH1A1MAPT | |
| SCHEMBL4474305 | 0.74 | HPGD (0.57) | GAAALDH1A1MAPTSMN1; SMN2PARP1 | |
| SCHEMBL28984179 | 0.71 | TAAR1 (0.46) | AXLSORT1ALDH1A1SMN1; SMN2CALM1 | |
| SCHEMBL16019686 | 0.69 | ALDH1A1 (0.48) | ALDH1A1MAPTSMN1; SMN2DHFRDAO | |
| SCHEMBL1659954 | 0.67 | — | — | |
| SCHEMBL2375581 | 0.67 | AXL (1.00) | AXLALDH1A1MAPTSMN1; SMN2MAOB | |
| SCHEMBL4496630 | 0.67 | SORT1 (0.46) | SORT1GAAALDH1A1DHFRCALM1 | |
| SCHEMBL11963994 | 0.67 | SORT1 (1.00) | SORT1GAAALDH1A1SMN1; SMN2DHFR | |
| SCHEMBL1325617 | 0.66 | CALM1 (0.55) | GAAALDH1A1SMN1; SMN2CALM1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0978568-B1 | Method for the prevention of hemoglobin interference in reagent systems for measuring peroxidase activity | BAYER AG (US) | 2004-09-29 | — | — | EP | claimed |
| US-6074881-A | TEST FOR THE ACTIVITY OF A METAL CHELATE IN A FLUID SAMPLE; FOR THE DETECTION OF CREATININE IN A URINE SAMPLE | BAYER CORPORATION (US) | 2000-06-13 | — | — | US | claimed |
| US-7550598-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| EP-1778669-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7060822-B1 | 2-pyrazolin-5-ones | ABBOTT GMBH & CO. KG (DE) | 2006-06-13 | — | — | US | disclosed |
| WO-2006023931-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | disclosed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| CN-1193026-C | Z-pyrazoline-5-ones | BASF AG (DE) | 2005-03-16 | — | — | CN | disclosed |
| CN-1377346-A | Z-pyrazoline-5-ones | BASF AG (DE) | 2002-10-30 | — | — | CN | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041137-A1 | Kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | AXL 424/4885SORT1 4627/4885GAA 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.